Human Research Ethics Committee approval received for Phase II trial of R327 for acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot and wound infections New site ...
Recce Pharmaceuticals Ltd (ASX:RCE) shareholders should be happy to see the share price up 20% in the last month. But that can't change the reality that over the longer term (five years), the returns ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Recce Pharmaceuticals Ltd. ( (AU:RCE)) ...
SYDNEY, Australia, July 08, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of synthetic anti-infectives, today announced it has entered ...
This new patent strengthens Recce’s intellectual property footprint across Asia, supporting its strategy to access high-growth ASEAN markets. The patent claims cover Recce Pharmaceuticals (ASX:RCE) ...
Recce Pharmaceuticals Ltd. (AU:RCE) has released an update. Recce Pharmaceuticals Ltd has completed a pivotal phase of its Phase I/II clinical trial by successfully dosing 6 subjects with a high-dose, ...
Phase 1/2 trial of RECCE ® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical Research Study will assess the ...
Recce Pharmaceuticals Ltd. (AU:RCE) has released an update. Recce Pharmaceuticals Ltd (ASX:RCE) successfully passed a resolution via poll at their Special General Meeting, marking a significant step ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results